Navigation Links
Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
Date:9/30/2013

HOUSTON, Sept. 30, 2013 /PRNewswire/ -- Moleculin, LLC, a clinical-stage pharmaceutical company focused on developing topical treatments for inflammatory and proliferative skin diseases, today announced positive results from a double-blind, randomized Phase 2a study with MOL4249, a novel compound in development for the treatment of psoriasis. In the study, MOL4249 was shown to be effective in the treatment of mild-to-moderate plaque psoriasis when compared to the vehicle, with no detectable side effects.

"Despite the many treatment options available today, psoriasis continues to be an underserved skin disease with need for improvements in both efficacy and long-term tolerability over available therapies," said Walter Klemp, Chairman and CEO of Moleculin. "The Phase 2 data for MOL4249 are very encouraging and support our plans for continued study in larger numbers of patients."

Study Details

The double-blind, controlled, Phase 2a study involved 16 patients with mild-to-moderate plaque psoriasis. Of these, 10 patients were treated with a topical compound containing MOL4249, while 6 were treated with a control vehicle. Patients applied the treatment twice a day for 28 consecutive days. 50% of patients treated with MOL4249 showed a 50% or better improvement in lesions, versus 17% for the vehicle. In addition, 30% of MOL4249 patients demonstrated a 75% or better improvement in lesions, versus 17% for the vehicle.

Patients and physicians reported no adverse events in the study, suggesting the potential of a topical treatment for psoriasis that is safe for long-term use. MOL4249 is a first-in-class small molecule drug that works by directly inhibiting p-STAT3, a novel target that may contribute to many chronic skin diseases regardless of its activating pathway. Data suggest that this unique mechanism of action may significantly reduce the incidence of side effects, making this compound safe for long-term, chronic use.

About Psoriasis

Psoriasis is a chronic autoimmune skin disease that occurs when the immune system mistakenly speeds up the growth cycle of skin cells. It affects up to 7.5 million Americans and can be difficult to treat because of side effects such as atrophy, or thinning of the skin, with long-term use.

Plaque psoriasis is the most common form of the disease in which people develop itchy skin spots, red patches, and a silvery white buildup of dead skin cells most often appearing on the scalp, lower back, knees, and elbows.

According to a patient survey conducted in the U.S. between 2001 and 2008 by the National Psoriasis Foundation, 33% of patients with mild disease and 60% of patients with moderate-to-severe psoriasis reported that their disease significantly affects their everyday life.

About Moleculin

Moleculin is a clinical-stage pharmaceutical company advancing a new therapeutic approach to inflammatory and proliferative skin diseases, including psoriasis, atopic dermatitis, actinic keratosis, and several skin cancers. The Company's topical compounds are based on the direct inhibition of activated STAT3 (p-STAT3), an important target in the fight against chronic skin diseases. MOL4249, the Company's lead product candidate, is currently being studied in psoriasis. Early clinical studies with this p-STAT3 inhibitor suggest improved efficacy and tolerability for the treatment of mild-to-moderate psoriasis. For more information, visit moleculin.com.


'/>"/>
SOURCE Moleculin, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Allied Healthcare Products Reports Loss On Sales Decline
3. TPI Reports Fiscal Year 2013 Financial Results
4. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
5. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
6. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
7. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
8. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
9. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
10. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
11. Omeros Reports Additional Positive Results from OMS824 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):